Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
Serena Di CosimoValentina AppiertoSara PizzamiglioPaola TiberioMarilena V IorioFlorentine S HilbersEvandro de AzambujaLorena de la PeñaMiguel IzquierdoJens HuoberJosé BaselgaMartine PiccartFilippo G de BraudGiovanni ApolonePaolo VerderioMaria Grazia DaidonePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
ct-miRNAs discriminate patients with and without pCR after neoadjuvant lapatinib- and/or trastuzumab-based therapy. ct-miRNAs at week two could be valuable to identify patients responsive to trastuzumab, to avoid unnecessary combination with other anti-HER2 agents, and finally to assist deescalating treatment strategies.
Keyphrases
- positive breast cancer
- rectal cancer
- end stage renal disease
- computed tomography
- lymph node
- epidermal growth factor receptor
- image quality
- metastatic breast cancer
- locally advanced
- newly diagnosed
- contrast enhanced
- dual energy
- chronic kidney disease
- ejection fraction
- clinical trial
- prognostic factors
- peritoneal dialysis
- magnetic resonance imaging
- stem cells
- cancer therapy
- phase iii
- combination therapy
- open label